Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer OTCs

This article was originally published in The Tan Sheet

Executive Summary

Pfizer Consumer Healthcare "has eliminated select contract sales forces in North America [and] reduced its advertising-agency expenditures through lowered fee structures and ongoing agency consolidation around the world on certain small and/or low-growth brands," the firm reports during third-quarter earnings announcement Oct. 20. Such efforts will lead to "increased value by better leveraging research across the business," Pfizer adds. Consumer division sales were $921 mil. worldwide, an 8% increase over sales of $851 mil. during the prior-year period. U.S. sales for the division were up 9% to $493 mil., compared to $453 mil. last year. Sales for the entire firm totaled $12.2 bil., a 5% increase over 2004...

You may also be interested in...



Sales Already Growing As Vascepa Secures Cardio Approval

Company forecasts 2020 sales as high as $700m after regulator grants broad label.

Another EU MDR Notified Body In The Netherlands

Last week, the Commission  revealed that three more notified bodies had been designated; but their listings had not been made official. Now we learn that one of the three is in the Netherlands as the first listing takes place.

Belgium Outlaws OTC Cough And Cold Combination Drugs

Safety concerns prompt Belgium's drug regulator to order all OTC fixed combination products for coughs and colds removed from shelves.

Topics

UsernamePublicRestriction

Register

PS098762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel